Fig. 2 | Nature Communications

Fig. 2

From: Biosynthesis of ilamycins featuring unusual building blocks and engineered production of enhanced anti-tuberculosis agents

Fig. 2

HPLC analyses of fermentation broths. (i) wild-type S. atratus SCSIO ZH16; (ii) ΔilaS mutant; (iii) ΔilaO mutant; (iv) ΔilaG mutant; (v) ΔilaE mutant; (vi) ΔilaD mutant n; (vii) ΔilaF mutant; (viii) ΔilaC mutant; (ix) ΔilaH mutant; (x) ΔilaD mutant fed with AHA; (xi) ΔilaD mutant fed with 4-HA; (xii) ΔilaE mutant fed with AHA; (xiii) ΔilaE mutant fed with 4-HA; (xiv) ΔilaE mutant fed with 2,4-HDA; (xv) ΔilaM mutant; (xvi) ΔilaN mutant; (xvii) ΔilaL mutant; (xviii) ΔilaM mutant fed with 3-NO2-tyr; (xix) ΔilaN mutant fed with 3-NO2-tyr; (xx) ΔilaR mutant; the peaks labeled with asterisks are not ilamycin analogs judged by HPLC–DAD–UV analysis

Back to article page